Annaliesa S. Anderson, PhD

SVP & CSO
Pfizer
New York, New York, United States

Disclosure(s): Pfizer, Inc.: Employee, Stocks/Bonds (Public Company)

Presentation(s):

• 571 - Safety and Immunogenicity of Coadministered Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine With and Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age

  Saturday, October 19, 2024
  1:45 PM – 2:03 PM US PT